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A 17-year-old male with type 1 diabetes mellitus (T1DM) presented to clinic with elevated transaminases and a positive
antinuclear antibody (ANA) screen. Due to concern for autoimmune hepatitis, a liver biopsy was performed which revealed
Mauriac syndrome. This case report is the second known description of a child with Mauriac syndrome presenting with positive
autoimmune markers.
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1.Introduction
Mauriac syndrome is associated with poor control of T1DM
and presents as hepatomegaly and elevated transaminases
[1]. It is typically associated with growth failure and delayed
pubertal maturation, although these eﬀects can be reversed
with good glycemic control [2].
2.CaseReport
A 17-year-old male was referred to the pediatric gastroen-
terology clinic due to elevated transaminases noted during
standard screening blood work. The patient had a history
of type I diabetes mellitus (T1DM) diagnosed since 5 years
of age with the patient having multiple hospital admissions
for diabetic ketoacidosis secondary to noncompliance with
insulin therapy. Past medical history was signiﬁcant for
p y l o r i cs t e n o s i sr e p a i ra t4w e e k so fa g ea n dap r i o r
history of tonsillectomy and adenoidectomy. Family history
was noncontributory. His current medication consisted of
Humalog Mix 75/25 insulin (Eli Lilly and Company) with
the patient receiving approximately 1.3 units of insulin per
kilogram body weight.
The patient had no history of jaundice or scleral icterus,
and he denied right upper quadrant pain, pruritis, weight
loss, ascites, hematemesis, or rectal bleeding. A review of his
blood glucose monitoring demonstrated a range of 250–310
milligram per deciliter (mg/dL), and he had a hemoglobin
A1c of 12.3% suggesting poor glycemic control.
A liver ultrasound showed normal hepatic echotex-
ture and minimal sludge in the gallbladder (Figure 1). A
complete blood count, prothrombin time, activated par-
tial thromboplastin time, lipid panel, free thyroxine level,
and tissue transglutaminase serum IgA level were normal.
However, transaminases were elevated with an aspartate
aminotransferase(AST)andalanineaminotransferase(ALT)
consisting of 63 international units per liter (IU/L) and
209IU/L,respectively.Directbilirubin,alkalinephosphatase,
and gamma-glutamyl transpeptidase levels were normal. A
viral hepatitis panel, serum ceruloplasmin, and alpha 1-
antitrypsin phenotype were normal. The patient was noted
to have an elevated ANA titer (1 : 160 in a homogenous pat-
tern). Screening for smooth muscle antibody was negative,
and it was decided that a percutaneous liver biopsy should
be performed due to the possibility of type 1 autoimmune
hepatitis.
A subsequent liver biopsy demonstrated normal por-
t a lt r a c t s( H & E1 0 0 ×, Figure 2(a)); however, hepatocytes
demonstrated cytoplasmic clearing secondary to increased
intracellular glycogen and microvesicular fat (H&E 200×,
Figure 2(b)). This biopsy was consistent with Mauriac syn-
drome and the importance of improved adherence to insulin
therapy was expressed to the patient and his family.2 Gastroenterology Research and Practice
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3. Discussion
Mauriac syndrome, ﬁrst described in 1947, is a rare com-
plication associated with T1DM and is typically associated
with poor insulin compliance and glycemic control [1].
Although hepatomegaly and elevated serum transaminases
are common ﬁndings in Mauriac syndrome, other described
pediatric manifestations can include malnutrition, growth
failure, and development of cushingoid features [1, 2].
Malnutrition associated with poor T1DM control also can
lead to false elevation of the sweat chloride concentration, so
suchpatientscanpresentwithfalse-positivescreensforcystic
ﬁbrosis [3].
T1DM is associated with other autoimmune diseases,
including celiac disease and autoimmune thyroiditis, and it
is common for patients with T1DM to have elevated autoan-
tibody titers [4]. Only one prior case report has described
Mauriac syndrome in the setting of positive autoantibodies.
Inthiscase,a16-year-oldmalewithpoorlycontrolledT1DM
presented with elevated serum transaminases and a positive
ANAof1 : 640.Asubsequentliverbiopsywasconsistentwith
Mauriac syndrome [5].
Typically, a liver biopsy in the setting of Mauriac
syndrome will demonstrate steatosis as well as glycogen
deposition although such ﬁndings can vary in presentation
[6, 7]. Poor T1DM control leads to fatty acid transport to
the liver, due to hyperglycemia and low insulin levels, which
causes hepatomegaly and characteristic liver biopsy ﬁndings.
These ﬁndings reverse with improved insulin control [8].
4. Conclusions
Mauriac syndrome is a rare complication of T1DM. Liver
biopsy may be warranted in any patient with T1DM and
positive autoimmune markers in order to rule out autoim-
mune hepatitis. Further studies are needed to help delineate
patients with Mauriac syndrome from those patients with
autoimmune hepatitis.
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